Provided by Tiger Trade Technology Pte. Ltd.

Atai Beckley Inc

7.35
0.0000
Volume:- -
Turnover:- -
Market Cap:2.72B
PE:-3.44
High:7.35
Open:7.35
Low:7.35
Close:7.35
52wk High:7.45
52wk Low:3.27
Shares:369.95M
Float Shares:297.06M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1359
EPS(LYR):-2.9137
ROE:-417.21%
ROA:-39.03%
PB:15.42
PE(LYR):-2.52

Loading ...

BUZZ-Psychedelic drug developers rise after Trump signals regulatory support

Reuters
·
Apr 20

ATAI Life Sciences Is Maintained at Buy by Guggenheim

Dow Jones
·
Apr 17

BUZZ-Psychedelic drug developers rise after CBS report Trump backs more research

Reuters
·
Apr 17

Atai Beckley CEO joins Needham Virtual Healthcare Conference fireside chat

Reuters
·
Apr 14

AtaiBeckley says BPL-003 hits 67% Day-2 response in Phase 2a TRD study

Reuters
·
Apr 08

Is It Time To Reassess AtaiBeckley (ATAI) After Its Recent Share Price Slide?

Simply Wall St.
·
Mar 30

Is Psychedelic Nasal Spray Data And Index Inclusion Altering The Investment Case For AtaiBeckley (ATAI)?

Simply Wall St.
·
Mar 28

ATAI Life Sciences Initiated at Buy by Deutsche Bank

Dow Jones
·
Mar 27

U.S. RESEARCH ROUNDUP- Brown-Forman, Chord Energy, Olaplex Holdings

Reuters
·
Mar 27

AtaiBeckley initiated with a Buy at Deutsche Bank

TIPRANKS
·
Mar 27

A Look At AtaiBeckley (ATAI) Valuation After Index Inclusions And Positive BPL-003 Phase 2a Results

Simply Wall St.
·
Mar 26

AtaiBeckley Chief Medical Officer Craig Kevin James disposes of USD 355,000 in common shares

Reuters
·
Mar 25

AtaiBeckley Joins CRSP U.S. Benchmark Indices Tracking USD 3 trillion

Reuters
·
Mar 24

Weighing AtaiBeckley (ATAI) Valuation After Recent Share Price Volatility

Simply Wall St.
·
Mar 18

ATAI Life Sciences Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 18

BRIEF-Bpl-003 Demonstrates Rapid And Durable Antidepressant Effects In Treatment-Resistant Depression Phase 2A Data Published In Journal Of Psychopharmacology Phase 3 Program On Track For Q2 2026 Initiation

Reuters
·
Mar 17

Atai Beckley’s BPL-003 Phase 2a trial in treatment-resistant depression shows 12.6-point MADRS reduction by Day 2

Reuters
·
Mar 17